Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
16.98
-0.03 (-0.18%)
Dec 20, 2024, 4:00 PM EST - Market closed
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 216.00K CHF in the quarter ending September 30, 2024, a decrease of -1.37%. This brings the company's revenue in the last twelve months to 868.00K, down -4.82% year-over-year. In the year 2023, Oculis Holding AG had annual revenue of 883.00K, down -3.18%.
Revenue (ttm)
868.00K CHF
Revenue Growth
-4.82%
P/S Ratio
n/a
Revenue / Employee
24,111 CHF
Employees
36
Market Cap
712.23M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
Dec 31, 2020 | 993.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOCS News
- 15 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 22 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - GlobeNewsWire
- 24 days ago - Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - GlobeNewsWire
- 5 weeks ago - Oculis to Present at the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewsWire
- 2 months ago - Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees - GlobeNewsWire
- 2 months ago - Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 - GlobeNewsWire
- 2 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire